Myriad Genetics, Inc. (0K3W.L)
USD 14.11
(0.53%)
USD 14.11
(0.53%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2022 | 678.4 Million USD | -1.77% |
| 2021 | 690.6 Million USD | 23.99% |
| 2020 | 557 Million USD | -34.56% |
| 2019 | 851.1 Million USD | 0.0% |
| 2018 | 851.1 Million USD | 10.16% |
| 2017 | 772.6 Million USD | 0.16% |
| 2016 | 771.4 Million USD | 2.33% |
| 2015 | 753.8 Million USD | 4.25% |
| 2014 | 723.1 Million USD | -7.08% |
| 2013 | 778.21 Million USD | 26.92% |
| 2012 | 613.16 Million USD | 23.62% |
| 2011 | 496 Million USD | 23.36% |
| 2010 | 402.08 Million USD | 10.87% |
| 2009 | 362.64 Million USD | 11.06% |
| 2008 | 326.52 Million USD | -2.13% |
| 2007 | 333.62 Million USD | 112.33% |
| 2006 | 157.12 Million USD | 37.49% |
| 2005 | 114.27 Million USD | 38.68% |
| 2004 | 82.4 Million USD | 45.47% |
| 2003 | 56.64 Million USD | -11.93% |
| 2002 | 64.32 Million USD | 19.47% |
| 2001 | 53.83 Million USD | 19.21% |
| 2000 | 45.16 Million USD | 32.78% |
| 1999 | 34.01 Million USD | 34.44% |
| 1998 | 25.3 Million USD | 9.05% |
| 1997 | 23.2 Million USD | 52.63% |
| 1996 | 15.2 Million USD | 130.3% |
| 1995 | 6.6 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q1 | 181.2 Million USD | 1.91% |
| 2023 Q3 | 191.9 Million USD | 4.58% |
| 2023 Q2 | 183.5 Million USD | 1.27% |
| 2022 Q4 | 177.8 Million USD | 13.68% |
| 2022 Q3 | 156.4 Million USD | -12.77% |
| 2022 Q2 | 179.3 Million USD | 8.73% |
| 2022 Q1 | 164.9 Million USD | 2.55% |
| 2022 FY | 678.4 Million USD | -1.77% |
| 2021 Q4 | 160.8 Million USD | -3.89% |
| 2021 Q2 | 189.4 Million USD | 9.42% |
| 2021 Q1 | 173.1 Million USD | 11.97% |
| 2021 FY | 690.6 Million USD | 23.99% |
| 2021 Q3 | 167.3 Million USD | -11.67% |
| 2020 Q3 | 145.2 Million USD | 55.79% |
| 2020 FY | 557 Million USD | -34.56% |
| 2020 Q2 | 93.2 Million USD | -43.17% |
| 2020 Q1 | 164 Million USD | -15.94% |
| 2020 Q4 | 154.6 Million USD | 6.47% |
| 2019 Q1 | 216.6 Million USD | -0.09% |
| 2019 Q2 | 215.4 Million USD | -0.55% |
| 2019 Q3 | 186.3 Million USD | -13.51% |
| 2019 Q4 | 195.1 Million USD | 4.72% |
| 2019 FY | 851.1 Million USD | 0.0% |
| 2018 Q2 | 200.9 Million USD | 3.82% |
| 2018 Q4 | 216.8 Million USD | 7.17% |
| 2018 FY | 851.1 Million USD | 10.16% |
| 2018 Q1 | 193.5 Million USD | -0.26% |
| 2018 Q3 | 202.3 Million USD | 0.7% |
| 2017 Q1 | 196.9 Million USD | 0.2% |
| 2017 Q4 | 194 Million USD | 2.0% |
| 2017 FY | 772.6 Million USD | 0.16% |
| 2017 Q3 | 190.2 Million USD | -5.14% |
| 2017 Q2 | 200.5 Million USD | 1.83% |
| 2016 Q4 | 196.5 Million USD | 10.7% |
| 2016 Q2 | 186.5 Million USD | -2.1% |
| 2016 Q1 | 190.5 Million USD | -1.45% |
| 2016 FY | 771.4 Million USD | 2.33% |
| 2016 Q3 | 177.5 Million USD | -4.83% |
| 2015 Q3 | 183.5 Million USD | -3.37% |
| 2015 FY | 753.8 Million USD | 4.25% |
| 2015 Q1 | 179.98 Million USD | -2.39% |
| 2015 Q2 | 189.9 Million USD | 5.51% |
| 2015 Q4 | 193.3 Million USD | 5.34% |
| 2014 Q3 | 168.83 Million USD | -10.56% |
| 2014 Q4 | 184.39 Million USD | 9.21% |
| 2014 FY | 723.1 Million USD | -7.08% |
| 2014 Q1 | 182.92 Million USD | -10.36% |
| 2014 Q2 | 188.76 Million USD | 3.19% |
| 2013 Q2 | 174.11 Million USD | 11.28% |
| 2013 Q1 | 156.47 Million USD | 4.92% |
| 2013 FY | 778.21 Million USD | 26.92% |
| 2013 Q4 | 204.06 Million USD | 0.79% |
| 2013 Q3 | 202.46 Million USD | 16.28% |
| 2012 FY | 613.16 Million USD | 23.62% |
| 2012 Q1 | 129.77 Million USD | 5.67% |
| 2012 Q4 | 149.14 Million USD | 11.77% |
| 2012 Q3 | 133.43 Million USD | 0.35% |
| 2012 Q2 | 132.96 Million USD | 2.46% |
| 2011 Q2 | 107.41 Million USD | 4.92% |
| 2011 Q4 | 122.81 Million USD | 11.19% |
| 2011 FY | 496 Million USD | 23.36% |
| 2011 Q1 | 102.37 Million USD | 1.93% |
| 2011 Q3 | 110.45 Million USD | 2.83% |
| 2010 FY | 402.08 Million USD | 10.87% |
| 2010 Q3 | 91.85 Million USD | -2.2% |
| 2010 Q2 | 93.92 Million USD | 3.41% |
| 2010 Q1 | 90.83 Million USD | -2.09% |
| 2010 Q4 | 100.44 Million USD | 9.34% |
| 2009 Q1 | 87.48 Million USD | 3.69% |
| 2009 Q4 | 92.76 Million USD | 8.98% |
| 2009 Q3 | 85.12 Million USD | 5.07% |
| 2009 Q2 | 81.01 Million USD | -7.4% |
| 2009 FY | 362.64 Million USD | 11.06% |
| 2008 Q1 | 61.76 Million USD | 8.85% |
| 2008 FY | 326.52 Million USD | -2.13% |
| 2008 Q4 | 84.37 Million USD | 14.56% |
| 2008 Q3 | 73.65 Million USD | -55.86% |
| 2008 Q2 | 166.85 Million USD | 170.15% |
| 2007 Q3 | 48.26 Million USD | 6.13% |
| 2007 Q2 | 45.47 Million USD | 11.0% |
| 2007 Q1 | 40.97 Million USD | 10.33% |
| 2007 FY | 333.62 Million USD | 112.33% |
| 2007 Q4 | 56.74 Million USD | 17.56% |
| 2006 Q2 | 32.02 Million USD | 7.43% |
| 2006 Q1 | 29.8 Million USD | 9.07% |
| 2006 FY | 157.12 Million USD | 37.49% |
| 2006 Q4 | 37.13 Million USD | 10.71% |
| 2006 Q3 | 33.54 Million USD | 4.74% |
| 2005 Q4 | 27.33 Million USD | 8.82% |
| 2005 FY | 114.27 Million USD | 38.68% |
| 2005 Q2 | 26.09 Million USD | 30.73% |
| 2005 Q1 | 19.96 Million USD | 1.64% |
| 2005 Q3 | 25.11 Million USD | -3.76% |
| 2004 Q2 | 15.07 Million USD | 9.57% |
| 2004 Q1 | 13.75 Million USD | -2.77% |
| 2004 Q3 | 16.71 Million USD | 10.87% |
| 2004 Q4 | 19.63 Million USD | 17.53% |
| 2004 FY | 82.4 Million USD | 45.47% |
| 2003 Q1 | 16.08 Million USD | -5.47% |
| 2003 Q2 | 15.7 Million USD | -2.39% |
| 2003 Q3 | 13.67 Million USD | -12.94% |
| 2003 FY | 56.64 Million USD | -11.93% |
| 2003 Q4 | 14.14 Million USD | 3.48% |
| 2002 Q4 | 17.01 Million USD | 9.72% |
| 2002 FY | 64.32 Million USD | 19.47% |
| 2002 Q3 | 15.51 Million USD | 9.91% |
| 2002 Q2 | 14.11 Million USD | 8.07% |
| 2002 Q1 | 13.05 Million USD | -3.1% |
| 2001 Q4 | 13.47 Million USD | 2.16% |
| 2001 FY | 53.83 Million USD | 19.21% |
| 2001 Q1 | 11.56 Million USD | -3.23% |
| 2001 Q2 | 10.82 Million USD | -6.44% |
| 2001 Q3 | 13.19 Million USD | 21.88% |
| 2000 FY | 45.16 Million USD | 32.78% |
| 2000 Q4 | 11.95 Million USD | 10.49% |
| 2000 Q1 | 9.71 Million USD | 17.05% |
| 2000 Q2 | 9.15 Million USD | -5.74% |
| 2000 Q3 | 10.81 Million USD | 18.15% |
| 1999 Q2 | 6.9 Million USD | -2.82% |
| 1999 Q1 | 7.1 Million USD | 24.56% |
| 1999 FY | 34.01 Million USD | 34.44% |
| 1999 Q4 | 8.3 Million USD | 20.29% |
| 1999 Q3 | 6.9 Million USD | 0.0% |
| 1998 Q4 | 5.7 Million USD | 1.79% |
| 1998 FY | 25.3 Million USD | 9.05% |
| 1998 Q1 | 5.7 Million USD | 11.76% |
| 1998 Q2 | 6.5 Million USD | 14.04% |
| 1998 Q3 | 5.6 Million USD | -13.85% |
| 1997 Q1 | 2.7 Million USD | -3.57% |
| 1997 Q2 | 7.5 Million USD | 177.78% |
| 1997 Q3 | 5.9 Million USD | -21.33% |
| 1997 FY | 23.2 Million USD | 52.63% |
| 1997 Q4 | 5.1 Million USD | -13.56% |
| 1996 Q3 | 2.2 Million USD | 10.0% |
| 1996 FY | 15.2 Million USD | 130.3% |
| 1996 Q1 | 1.9 Million USD | 11.76% |
| 1996 Q4 | 2.8 Million USD | 27.27% |
| 1996 Q2 | 2 Million USD | 5.26% |
| 1995 Q4 | 1.7 Million USD | 70.0% |
| 1995 FY | 6.6 Million USD | 0.0% |
| 1995 Q3 | 1 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Editas Medicine, Inc. | 78.12 Million USD | -768.374% |
| Dynavax Technologies Corporation | 232.28 Million USD | -192.056% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -11.667% |
| Perrigo Company plc | 4.65 Billion USD | 85.428% |
| Illumina, Inc. | 4.5 Billion USD | 84.938% |
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 98.417% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -56956.35% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 99.541% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 95.473% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -433.988% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 94.828% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Waters Corporation | 2.95 Billion USD | 77.053% |
| Biogen Inc. | 9.83 Billion USD | 93.103% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -284.947% |
| Evolus, Inc. | 202.08 Million USD | -235.7% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -3135.406% |
| bluebird bio, Inc. | 29.49 Million USD | -2199.895% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -483.149% |
| FibroGen, Inc. | 147.75 Million USD | -359.148% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 90.072% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Homology Medicines, Inc. | -6.65 Million USD | 10299.97% |
| Geron Corporation | 237 Thousand USD | -286144.726% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 62.894% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -69.873% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -1770.159% |
| Zoetis Inc. | 8.54 Billion USD | 92.06% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -19282.857% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 82.092% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 71.958% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 93.126% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 13.87% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -7813.216% |
| Verastem, Inc. | - USD | -Infinity% |
| Nektar Therapeutics | 90.12 Million USD | -652.757% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -150.702% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -2070.949% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 45.437% |
| OPKO Health, Inc. | 863.49 Million USD | 21.436% |
| Exelixis, Inc. | 1.83 Billion USD | 62.933% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 64.051% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -40.637% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | -4182.017% |
| Imunon, Inc. | - USD | -Infinity% |
| Blueprint Medicines Corporation | 249.38 Million USD | -172.035% |
| Insmed Incorporated | 305.2 Million USD | -122.275% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 18.191% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -2429.173% |
| TG Therapeutics, Inc. | 233.66 Million USD | -190.334% |
| Incyte Corporation | 3.69 Billion USD | 81.643% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | 35.347% |